Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04500756
PHASE2

Limiting AAA With Metformin (LIMIT) Trial

Sponsor: Stanford University

View on ClinicalTrials.gov

Summary

In this research, the investigators are looking at the effects of a drug called metformin may have on the growth of abdominal aortic aneurysm (AAA)s. AAA is an abnormal enlargement of the aorta, which is the large artery in the abdomen (stomach area). The enlargement of the aorta carries a risk that it will rupture and cause life-threatening bleeding in the abdomen (belly). In this study the investigators hope to learn how metformin is associated with the enlargement or change in size of the AAA in study participants. Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?

Official title: LIMItIng AAA With meTformin (LIMIT) Trial

Key Details

Gender

All

Age Range

50 Years - 95 Years

Study Type

INTERVENTIONAL

Enrollment

314

Start Date

2022-02-28

Completion Date

2028-06-30

Last Updated

2025-04-18

Healthy Volunteers

No

Interventions

DRUG

Metformin

Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?

OTHER

Placebo

One group will be randomized to receive the study drug Metformin and the other group will receive a placebo

Locations (1)

Stanford Hospital and Clinics

Stanford, California, United States